AVXL - CIK 0001314052
ANAVEX LIFE SCIENCES CORP. (AVXL) reported net income of -$46.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$46.38M | -7.8% |
| FY 2024 | -$43.00M | +9.5% |
| FY 2023 | -$47.51M | +1.0% |
| FY 2022 | -$47.98M | -26.6% |
| FY 2021 | -$37.91M | -44.2% |
| FY 2020 | -$26.28M | +0.1% |
| FY 2019 | -$26.29M | -52.4% |
| FY 2018 | -$17.25M | -28.2% |
| FY 2017 |
ANAVEX LIFE SCIENCES CORP. (AVXL) reported net income of -$46.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, ANAVEX LIFE SCIENCES CORP.'s net income declined from -$7.31M to -$46.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$13.46M |
| +8.7% |
| FY 2016 | -$14.74M | -21.7% |
| FY 2015 | -$12.11M | -21.5% |
| FY 2014 | -$9.97M | -169.4% |
| FY 2013 | -$3.70M | +55.4% |
| FY 2012 | -$8.30M | -13.6% |
| FY 2011 | -$7.31M | - |